TAM
CRNX icon

Tiverton Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Tiverton Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$18K Hold
1,208
– – ﹤0.01% 707
2019
Q2 		$30K Hold
1,208
– – ﹤0.01% 675
2019
Q1 		$27K Buy
+1,208
New +$29.7K ﹤0.01% 644

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Tiverton Asset Management's CRNX Position: Q3 2019 in Review

Tiverton Asset Management held its Crinetics Pharmaceuticals (CRNX) position steady in Q3 2019 at 1,208 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #707.

Tiverton Asset Management first reported a position in CRNX in Q1 2019 and has held it in 3 quarters since. The position peaked at $30K in Q2 2019. 61 funds tracked by Wall St. Rank hold CRNX as of Q3 2019.

  • Tiverton Asset Management held 1,208 shares of Crinetics Pharmaceuticals worth $18K as of Q3 2019.
  • Tiverton Asset Management left its Crinetics Pharmaceuticals share count unchanged in Q3 2019.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #707 holding.
  • Tiverton Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2019 and has held it in 3 quarters since.
  • Tiverton Asset Management's Crinetics Pharmaceuticals position peaked at $30K in Q2 2019.
  • 61 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.